Engineering a label-free electrochemical immunoassay for rapid quantification of fasting blood glucose using graphene-based aptamer sensors

Project Abstract

The development of a rapid, label-free electrochemical immunoassay leveraging graphene-based aptamer sensors offers a transformative approach for quantifying fasting blood glucose with high sensitivity, specificity, and operational simplicity. This study presents a novel biosensing platform that integrates a reduced graphene oxide (rGO)–supported aptamer functionalization with a label-free amperometric readout to enable direct detection of glucose-associated biomarkers in clinical samples. The core concept hinges on the high surface area, excellent electrical conductivity, and biocompatibility of graphene derivatives to facilitate dense aptamer loading and efficient electron transfer, thereby achieving low detection limits without complex labeling procedures. Aptamer sequences were rationally designed to target key glucose-related analytes, including insulin fragments and advanced glycation end products (AGEs) that correlate with fasting glucose status, while minimizing cross-reactivity with endogenous serum components. The sensor fabrication employed a scalable screen-printed carbon electrode (SPCE) platform, onto which a multi-layer assembly of chitosan, rGO, and thiolated aptamers was immobilized via robust covalent linkages to ensure stability under physiological conditions. Electrochemical readouts were realized through a differential pulse voltammetry (DPV) and chronoamperometry scheme, enabling rapid signal generation within minutes of sample introduction. In the presence of target glucose-related biomarkers, conformational changes in the aptamer modulated the interfacial electron transfer, producing a quantifiable current response proportional to the analyte concentration. The optimization phase explored aptamer density, surface passivation, pH, ionic strength, and incubation times to maximize sensitivity and dynamic range. Calibration across clinically relevant fasting glucose levels demonstrated a limit of detection in the low micromolar range with a broad linear dynamic range suitable for normoglycemic and hyperglycemic states. The biofouling resistance imparted by the graphene substrate, coupled with selective blocking of non-specific sites, yielded excellent specificity against structurally related metabolites and interfering proteins. The assay demonstrated robust reproducibility across multiple sensors and batch-to-batch consistency, with acceptable intra- and inter-assay coefficients of variation. To validate clinical applicability, the platform was tested with prepared human serum and whole blood samples, with a straightforward minimal-preparation protocol that preserves sample integrity while minimizing processing time. Comparative analyses against standard enzymatic glucose assays showed strong concordance, underscoring the potential of the proposed method as a rapid diagnostic alternative that reduces reliance on enzymatic reagents and bulky instrumentation. Mechanistic investigations revealed that electron transfer efficiency is modulated by the electrochemical environment at the graphene–aptamer interface, where charge transfer resistance decreases upon target binding, thereby amplifying the measurable signal. The study also assessed stability, shelf-life, and reusability parameters to address practical deployment in point-of-care settings. Overall, the engineered label-free graphene-based aptamer immunosensor demonstrates high sensitivity, rapid analysis, and operational simplicity, positioning it as a promising tool for early detection and continuous monitoring of fasting glucose status in clinical and home-care environments.

Project Overview

What This Project Is About

---

A beginner-friendly introduction to creating a simple sensor system that can measure blood sugar quickly without using tagged antibodies. The project uses a special carbon material (graphene) and small, specific DNA-like molecules (aptamers) to recognize glucose and send an easy-to-read electronic signal. The goal is to build a low-cost, easy-to-use device that can quantify fasting blood glucose levels in minutes.

---

---

The Problem It Addresses

---

Current glucose tests can be slow or require expensive components. There is a need for a fast, affordable, and accurate method that can be used in basic labs or clinics to help people manage diabetes. This project aims to fill that gap by combining a label-free sensing approach with a graphene-based platform.

---

---

Objectives of the Project

---

1. Understand how graphene enhances sensor signals and why aptamers are useful for glucose recognition.
2. Design a label-free electrochemical setup that produces a readable signal when glucose is present.
3. Develop a simple protocol for preparing the sensor and running measurements.
4. Evaluate the sensor’s performance, including sensitivity, selectivity, and response time.
5. Compare results with standard glucose tests to assess accuracy.
6. Identify practical limitations and suggest improvements for real-world use.

---

---

What You Will Do Step by Step

---

1. Review basics of electrochemical sensing and graphene’s role in signal enhancement.
2. Prepare graphene-based sensor electrodes and attach aptamers that bind glucose.
3. Calibrate the device using known glucose concentrations.
4. Test the sensor with unknown samples and record electrical responses.
5. Analyze data to create a concentration-to-signal relationship.
6. Assess repeatability, stability, and potential interference from common substances.
7. Document procedures, results, and compare with standard methods.
8. Propose improvements for portability and user-friendliness.

---

---

Expected Outcome

The project is expected to yield a working, label-free electrochemical sensor that can quantify fasting glucose with reasonable accuracy, fast response, and low cost. The study should demonstrate the feasibility of graphene-aptamer sensors for glucose measurement and provide a clear path toward simpler, point-of-care testing.